UAE to Ban Veterinary Use of Ciprofloxacin From November 1

The United Arab Emirates will prohibit the veterinary use of ciprofloxacin starting November 1, according to a report by UA.NEWS. The ban removes one of the most widely used fluoroquinolone antibiotics from the legal formulary for animals in the country.

Ciprofloxacin belongs to the fluoroquinolone class, a group of critically important antimicrobials in human medicine. Regulators in many jurisdictions have already restricted fluoroquinolone use in food animals because of resistance concerns that carry direct public-health consequences.

The UAE decision, effective November 1, follows that global pattern. The report does not specify which UAE authority issued the measure, nor whether the ban covers all animal species or applies only to food-producing animals.

What changes for veterinary practice?

From November 1, veterinarians practicing in the UAE can no longer legally use ciprofloxacin in animals. Clinics and hospitals that stock the drug will need to review inventories and prescribing protocols before the effective date.

The change is most consequential for food-animal and poultry practice, where fluoroquinolones have historically treated bacterial respiratory and enteric infections. Companion-animal practitioners who use the drug for resistant bacterial infections will also need alternatives once the prohibition takes effect.

The UA.NEWS report does not detail which substitute products, if any, UAE regulators have approved for the indications currently covered by ciprofloxacin.

Why do fluoroquinolone bans matter for public health?

Fluoroquinolones rank among the antimicrobial classes that human medicine relies on most heavily. Resistance that develops in animal pathogens, particularly in poultry and livestock, can transfer to bacteria that infect people through the food chain.

Governments that restrict these drugs in animals aim to preserve their effectiveness for human patients. The UAE ban, once active, aligns the country with jurisdictions that have already limited or removed fluoroquinolones from veterinary use.

The report does not cite specific resistance data or outbreak figures behind the UAE decision.

What should practitioners and suppliers do now?

Veterinary practices in the UAE face a clear deadline. Before November 1, they must confirm which ciprofloxacin products sit on their shelves, adjust treatment protocols, and identify licensed alternatives for the infections they currently manage with the drug.

Distributors and pharmacies that supply veterinary ciprofloxacin into the UAE market will need to halt sales of the affected products by the same date. The report does not state whether a transition period, product recall, or disposal scheme will accompany the ban.

Practitioners outside the UAE should also take note. Antimicrobial restrictions of this kind often signal a broader regional direction, and clients with cross-border livestock or equine operations may face differing rules country by country.

The ban takes effect November 1, and its enforcement details, exemptions, and replacement guidance should become clearer as the date approaches.

By Daniel Okafor, The Vet Scope